Interactions between osteoclasts, osteoblasts and immune cells: Implications for the pathogenesis of bone loss in thalassemia

Pediatric Endocrinology Reviews

Volumn 6, Issue SUPPL. 1, 2008, Pages 94-106

  Terpos, Evangelos ^a   Voskaridou, Ersi ^b  

^a 251 GENERAL AIR FORCE HOSPITAL   (Greece)

^b LAIKO GENERAL HOSPITAL   (Greece)

Author keywords

Bone markers; Dickkopf 1; Osteoclasts; Osteoporosis; Osteoprotegerin; RANKL; Thalassemia; Wnt signaling

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME 5B; ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; BIOLOGICAL MARKER; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1; CYTOKINE; DEOXYPYRIDINOLINE; HYDROXYLYSINE; HYDROXYPROLINE; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; PLACEBO; PROCOLLAGEN; PYRIDINOLINE; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

BONE CELL; BONE DESTRUCTION; BONE DISEASE; BONE REMODELING; CELL ACTIVATION; CELL FUNCTION; CELL INTERACTION; CLINICAL TRIAL; HUMAN; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; OSTEOBLAST; OSTEOCLAST; OSTEOCYTE; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PATHOGENESIS; REVIEW; THALASSEMIA;

BONE DISEASES; CELL COMMUNICATION; HUMANS; IMMUNE SYSTEM; OSTEOBLASTS; OSTEOCLASTS; THALASSEMIA;

EID: 58149512948     PISSN: 15654753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (138)

1. Seeman E, Delmas PD. Bone quality-the material and structural basis of bone strength and fragility. N Engl J Med 2006;354:2250-2261
2. Walsh MC, Kim N, Kadono Y, Rho J, Lee SY, Lorenzo J, Choi Y. Osteoimmunology: interplay between the immune system and bone metabolism. Annu Rev Immunol 2006;24:33-63
3. Lorenzo J, Horowitz M, Choi Y. Osteoimmunology: interactions of the bone and immune system. Endocr Rev 2008;29:403-440
4. Voskaridou E, Terpos E. New insights into the pathophysiology and management of osteoporosis in patients with beta thalassaemia. Br J Haematol 2004;127:127-139
5. Mundy GR. Cellular and molecular regulation of bone turnover. Bone 1999;24(5 Suppl):35S-38S
6. Christenson RH. Biochemical markers of bone metabolism: an overview. Clin Biochem 1997;30:573-593
7. Hodge JM, Kirkland MA, Aitken CJ, Waugh CM, Myers DE, Lopez CM, Adams BE, Nicholson GC. Osteoclastic potential of human CFU-GM: biphasic effect of GM-CSF. J Bone Miner Res 2004;19:190-199
8. Sminia T, Dijkstra CD. The origin of osteoclasts: an immunohistochemical study on macrophages and osteoclasts in embryonic rat bone. Calcif Tissue Int 1986;39:263-266
9. Tsurukai T, Takahashi N, Jimi E, Nakamura I, Udagawa N, Nogimori K, Tamura M, Suda T. Isolation and characterization of osteoclast precursors that differentiate into osteoclasts on calvarial cells within a short period of time. J Cell Physiol 1998;177:26-35
10. Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004;350:1655-1664
11. Goldring SR. Inflammatory mediators as essential elements in bone remodeling. Calcif Tissue Int 2003;73:97-100
12. Itoh K, Udagawa N, Matsuzaki K, Takami M, Amano H, Shinki T, Ueno Y, Takahashi N, Suda T. Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors. J Bone Miner Res 2000;15:1766-1775
13. Teitelbaum SL. Bone resorption by osteoclasts. Science 2000;289:1504-1508
14. Horowitz MC, Xi Y, Wilson K, Kacena MA. Control of osteoclastogenesis and bone resorption by members of the TNF family of receptors and ligands. Cytokine Growth Factor Rev 2001;12:9-18
15. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, Morony S, Oliveira dos Santos AJ, Van G, Itie A, Khoo W, Wakeham A, Dunstan CR, Lacey L, Mak TW, Boyle WJ, Penninger JM. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999;397:315-323
16. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-319
17. Morinaga T, Nakagawa N, Yasuda H, Tsuda E, Higashio K. Cloning and characterization of the gene encoding human osteoprotegerin/ osteoclastogenesis-inhibitory factor. Eur J Biochem 1998;254:685-691
18. Kim N, Odgren PR, Kim DK, Marks SC Jr, Choi Y. Diverse roles of the tumor necrosis factor family member TRANCE in skeletal physiology revealed by TRANCE deficiency and partial rescue by a lymphocyte-expressed TRANCE transgene. Proc Natl Acad Sci USA 2000;97:10905-10910
19. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ, Simonet WS. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998;12:1260-1268
20. Body JJ, Greipp P, Coleman RE, Facon T, Geurs F, Fermand JP, Harousseau JL, Lipton A, Mariette X, Williams CD, Nakanishi A, Holloway D, Martin SW, Dunstan CR, Bekker PJ. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 2003;97(3 Suppl):887-892
21. Vanderkerken K, Asosingh K, Croucher P, Van Camp B. Multiple myeloma biology: lessons from the 5TMM models. Immunol Rev 2003;194:196-206
22. Lipton A, Steger GG, Figueroa J, Alvarado C, Solal-Celigny P, Body JJ, de Boer R, Berardi R, Gascon P, Tonkin KS, Coleman R, Paterson AH, Peterson MC, Fan M, Kinsey A, Jun S. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Ciin Oncol 2007;25:4431-4437
23. Lewiecki EM, Miller PD, McClung MR, Cohen SB, Bolognese MA, Liu Y, Wang A, Siddhanti S, Fitzpatrick LA; AMG 162 Bone Loss Study Group. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J Bone Miner Res 2007;22:1832-1841
24. Cohen SB, Dore RK, Lane NE, Ory PA, Peterfy CG, Sharp JT, van der Heijde D, Zhou L, Tsuji W, Newmark R; Denosumab Rheumatoid Arthritis Study Group. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controtted, phase II clinical trial. Arthritis Rheum 2008;58:1299-1309
25. Aubin JE. Regulation of osteoblast formation and function. Rev Endocr Metab Disord 2001;2:81-94
26. Ahdjoudj S, Fromigue O, Marie PJ. Plasticity and regulation of human bone marrow stromal osteoprogenitor cells: potential implication in the treatment of age-related bone loss. Histol Histopathol 2004;19:151-157
27. Abe E, Yamamoto M, Taguchi Y, Lecka-Czernik B, O'Brien CA, Economides AN, Stahl N, Jilka RL, Manolagas SC. Essential requirement of BMPs-2/4 for both osteoblast and osteoclast formation in murine bone marrow cultures from adult mice: antagonism by noggin. J Bone Miner Res 2000;15:663-673
28. Power RA, Iwaniec UT, Magee KA, Mitova-Caneva NG, Wronski TJ. Basic fibroblast growth factor has rapid bone anabolic effects in ovariectomized rats. Osteoporos Int 2004;15:716-723
29. Cornish J, Grey A, Callon KE, Naot D, Hill BL, Lin CQ, Balchin LM, Reid IR. Shared pathways of osteoblast mitogenesis induced by amylin, adrenomedullin, and IGF-1. Biochem Biophys Res Commun 2004;318:240-246
30. Ortiz CO, Chen BK, Bale LK, Overgaard MT, Oxvig C, Conover CA. Transforming growth factor-beta regulation of the insulin-like growth factor binding protein-4 protease system in cultured human osteoblasts. J Bone Miner Res 2003;18:1066-1072
31. Chaudhary LR, Hofmeister AM, Hruska KA. Differential growth factor control of bone formation through osteoprogenitor differentiation. Bone 2004;34:402-411
32. Ducy P, Zhang R, Geoffroy V, Ridall AL, Karsenty G. Osf2/Cbfa1: a transcriptional activator of osteobtast differentiation. Cell 1997;89:747-754
33. Celeste AJ, Iannazzi JA, Taylor RC, Hewick RM, Rosen V, Wang EA, Wozney JM. Identification of transforming growth factor beta family members present in bone inductive protein purified from bovine bone. Proc Natl Acad Sci USA 1990;87:9843-9847
34. Bennett CN, Longo KA, Wright WS, Suva LJ, Lane TF, Hankenson KD, MacDougald OA. Regulation of osteoblastogenesis and bone mass by Wnt10b. Proc Natl Acad Sci USA 2005;102:3324-3329
35. Boyden LM, Mao J, Belsky J, Mitzner L, Farhi A, Mitnick MA, Wu D, Insogna K, Lifton RP. High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med 2002;346:1513-1521
36. Tamai K, Semenov M, Kato Y, Spokony R, Liu C, Katsuyama Y, Hess F, Saint-Jeannet JP, He X. LDL-receptor-related proteins in Wnt signal transduction. Nature 2000;407:530-535
37. He X, Semenov M, Tamai K, Zeng X. LDL receptor-related proteins 5 and 6 in Wnt/beta-catenin signaling: arrows point the way. Development 2004;131:1663-1677
38. Salazar VS, Mbalaviele G, Civitelli R. The pro-osteogenic action of beta-catenin requires interaction with BMP signaling, but not Tcf/Lef transcriptional activity. J Cell Biochem 2008;104:942-952
39. Krishnan V, Bryant HU, Macdougald OA. Regulation of bone mass by Wnt signaling. J Clin Invest 2006;116:1202-1209
40. Balemans W, Ebeling M, Patel N, Van Hul E, Olson P, Dioszegi M, Lacza C, Wuyts W, Van Den Ende J, Willems P, Paes-Alves AF, Hill S, Bueno M, Ramos FJ, Tacconi P, Dikkers, FG, Stratakis C, Lindpaintner K, Vickery B, Foernzler D, Van Hul W. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 2001;10:537-543
41. Bodine PV, Zhao W, Kharode YP, Bex FJ, Lambert AJ, Goad MB, Gaur T, Stein GS, Lian JB, Komm BS. The Wnt antagonist secreted frizzled-related protein-1 is a negative regulator of trabecular bone formation in adult mice. Mol Endocrinol 2004;18:1222-1237
42. Glinka A, Wu W, Delius H, Monaghan AP, Blumenstock C, Niehrs C. Dickkopf-1 is a member of a new family of secreted proteins and functions in head induction. Nature 1998;391:357-362
43. MacDonald BT, Joiner DM, Oyserman SM, Sharma F, Goldstein SA, He X, Hauschka PV. Bone mass is inversely proportional to Dkk1 levels in mice. Bone 2007;41:331-339
44. Aubin JE, Turksen K. Monoclonal antibodies as tools for studying the osteoblast lineage. Microsc Res Tech 1996;33:128-140
45. Noble BS. The osteocyte lineage. Arch Biochem Biophys 2009;473:106-111
46. van Bezooijen RL, Svensson JP, Eefting D, Visser A, van der Horst G, Karperien M, Quax PH, Vrieling H, Papapoulos SE, ten Dijke P, Löwik CW. Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation. J Bone Miner Res 2007;22:19-28
47. Heino TJ, Hentunen TA. Differentiation of osteoblasts and osteocytes from mesenchymal stem cells. Curr Stem Cell Res Ther 2008;3:131-145
48. Zhao S, Zhang YK, Harris S, Ahuja SS, Bonewald LF. MLO-Y4 osteocyte-like cells support osteoclast formation and activation. J Bone Miner Res 2002;17:2068-2079
49. Dunstan CR, Somers NM, Evans RA. Osteocyte death and hip fracture. Calcif Tissue Int 1993;53 Suppl 1:S113-S116; discussion S116-S117
50. Burr DB. Remodeling and the repair of fatigue damage. Calcif Tissue Int 1993;53(Suppl 1):S75-S80; discussion S80-S81
51. Martin TJ, Sims NA. Osteoclast-derived activity in the coupling of bone formation to resorption. Trends Mol Med 2005;11:76-81
52. Dougall WC, Glaccum M, Charrier K, Rohrbach K, Brasel K, De Smedt T, Daro E, Smith J, Tometsko ME, Maliszewski CR, Armstrong A, Shen V, Bain S, Cosman D, Anderson D, Morrissey PJ, Peschon JJ, Schuh J. RANK is essential for osteoclast and lymph node development. Genes Dev 1999;13:2412-2424
53. Lee SK, Gardner AE, Kalinowski JF, Jastrzebski SL, Lorenzo JA. RANKL stimulated osteoclast-like cell formation in vitro is partially dependent on endogenous interteukin-1 production. Bone 2005;38:678-685
54. Khapli SM, Mangashetti LS, Yogesha SD, Wani MR. IL-3 acts directly on osteoclast precursors and irreversibly inhibits receptor activator of NF-kappaB ligand-induced osteoclast differentiation by diverting the cells to macrophage lineage. J Immunol. 2003;171:142-151
55. Takahashi N, Udagawa N, Akatsu T, Tanaka H, Shionome M, Suda T. Role of colony-stimulating factors in osteoclast development. J Bone Miner Res 1991;6:977-985
56. Jimi E, Nakamura I, Duong LT, Ikebe T, Takahashi N, Rodan GA, Suda T. Interieukin 1 induces multinucleation and bone-resorbing activity of osteoclasts in the absence of osteoblasts/stromal cells. Exp Cell Res 1999;247:84-93
57. Hofbauer LC, Lacey DL, Dunstan CR, Spelsberg TC, Riggs BL, Khosla S. Interleukin-1 beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone 1999;25:255-259
58. Bertolini DR, Nedwin GE, Bringman TS, Smith DD, Mundy GR. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature 1986;319:516-518
59. Tashjian AH Jr, Voelkel EF, Lazzaro M, Goad D, Bosma T, Levine L. Tumor necrosis factor-alpha (Cachectin) stimulates bone resorption in mouse calvaria via a prostaglandin-mediated mechanism. Endocrinology 1987;120:2029-2036
60. Manolagas SC, Jilka RL. Mechanisms of disease: Bone marrow, cytokines, and bone remodeling-emerging insights into the pathophysiology of osteoporosis. N Eng J Med 1995;332:305-311
61. Morinaga Y, Fujita N, Ohishi K, Zhang Y, Tsuruo T. Suppression of interleukin-11-mediated bone resorption by cyclooxygenases inhibitors. J Cell Physiol 1998;175:247-254
62. Ryan MR, Shepherd R, Leavey JK, Gao YH, Grassi F, Schnell FJ, Qian WP, Kersh GJ, Weitzmann MN, Pacifici R. An IL-7-dependent rebound in thymic T cell output contributes to the bone loss induced by estrogen deficiency. Proc Natl Acad Sci USA 2005;102:16735-16740
63. Miranda-Carus ME, Benito-Miguel M, Balsa A, Cobo-Ibanez T, Perez de Ayala C, Pascual-Salcedo D, Martin-Mola E. Peripheral blood T lymphocytes from patients with early rheumatoid arthritis express RANKL and interleukin-15 on the cell surface and promote osteoclastogenesis in autologous monocytes. Arthritis Rheum 2006;54:1151-1164
64. Sato K, Suematsu A, Okamoto K, Yamaguchi A, Morishita Y, Kadono Y, Tanaka S, Kodama T, Akira S, Iwakura Y, Cua DJ, Takayanagi H. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 2006;203:2673-2682
65. Owens JM, Gallagher AC, Chambers TJ. IL-10 modulates formation of osteoctasts in murine hemopoietic cultures. J Immunol 1996;157:936-940
66. Van Vlasselaer P, Borremans B, Van Der Heuvel R, Van Gorp U, De Waal Malefyt R. Interleukin-10 inhibits the osteogenic activity of mouse bone marrow. Blood 1993;82:2361-2370
67. Hsieh CS, Macatonia SE, Tripp CS, Wolf SF, O'Garra A, Murphy KM. Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science 1993;260:547-549
68. Nanes MS, Rubin J, Titus L, Hendy GN, Catherwood B. Tumor necrosis factor-alpha inhibits 1,25-dihydroxyvitamin D 3 - stimulated bone Gla protein synthesis in rat osteosarcoma cells (ROS 17/2.8) by a pretranslational mechanism. Endocrinology 1991;128:2577-2580
69. Canalis E. Interleukin-1 has independent effects on deoxyribonucleic acid and collagen synthesis in cultures of rat calvariae. Endocrinology 1986;118:74-81
70. Centrella M, McCarthy TL, Canalis E. Tumor necrosis factor-alpha inhibits collagen synthesis and alkaline phosphatase activity independently of its effect on deoxyribonucleic acid synthesis in osteobtast-enriched bone cell cultures. Endocrinology 1988;123:1442-1448
71. Smith DD, Gowen M, Mundy GR. Effects of interferon-gamma and other cytokines on collagen synthesis in fetal rat bone cultures. Endocrinology 1987;120:2494-2499
72. Onoe Y, Miyaura C, Kaminakayashiki T, Nagai Y, Noguchi K, Chen QR, Seo H, Ohta H, Nozawa S, Kudo I, Suda T. IL-13 and IL-4 inhibit bone resorption by suppressing cyclooxygenase-2-dependent prostaglandin synthesis in osteoblasts. J Immunol 1996;156:758-764
73. Lind M, Deleuran B, Yssel H, Fink-Eriksen E, Thestrup-Pedersen K. IL-4 and IL-13, but not IL-10, are chemotactic factors for human osteoblasts. Cytokine 1995;7:78-82
74. Ura K, Morimoto I, Watanabe K, Saito K, Yanagihara N, Eto S. Interleukin (IL)-4 and IL-13 inhibit the differentiation of murine osteobtastic MC3T3-E1 cells. Endocr J 2000;47:293-305
75. Rifas L, Arackal S, Weitzmann MN. Inflammatory T cells rapidly induce differentiation of human bone marrow stromat cells into mature osteobtasts. J Cell Biochem 2003;88:650-659
76. Hannon RA, Eastell R. Biochemical markers of bone turnover and fracture prediction. J Br Menopause Soc 2003;9:10-15
77. Hannon RA, Clowes JA, Eagleton AC, Al Hadari A, Eastell R, Blumsohn A. Clinical performance of immunoreactive tartrate-resistant acid phosphatase isoform 5b as a marker of bone resorption. Bone 2004;34:187-194
78. Woitge HW, Pecherstorfer M, Horn E, Keck AV, Diet IJ, Bayer P, Ludwig H, Ziegler R, Seibel MJ. Serum bone sialoprotein as a marker of tumour burden and neoplastic bone involvement and as a prognostic factor in multiple myeloma. Br J Cancer 2001;84:344-351
79. Seibel MJ. Biochemical markers of bone metabolism in the assessment of osteoporosis: useful or not? J Endocrinol Invest 2003;26:464-471
80. Calvo MS, Eyre DR, Gundberg CM. Molecular basis and clinical application of biological markers of bone turnover. Endocrine Rev 1996;17:333-368
81. Meilman E, Urivetzky MM, Rapoport CM. Urinary hydroxyproline peptides. J Clin Invest 1963;42:40-50
82. Prockop DJ, Keiser HR, Sjoerdsma A. Gastrointestinal absorption and renal excretion of hydroxyproline peptides. Lancet 1962;2:527-528
83. Segrest JP. Urinary metabolites of collagen. Methods Enzymol 1982;82:398-410
84. Prockop DJ, Kivirikko KI. Collagens: molecular biology, diseases, and potentials for therapy. Annu Rev Biochem 1995;64:403-434
85. Askenasi R, Rao VH, Devos A. Peptide-bound hydroxylysine and large polypeptides related to collagen synthesis. Eur J Clin Invest 1976;6:361-363
86. Arlaud GJ, Gaboriaud C, Thielens NM, Rossi V. Structural biology of C1. Biochem Soc Trans 2002;30:1001-1006
87. Eyre DR. Bone biomarkers as tools in osteoporosis management. Spine 1997;22(Suppl 24):17S-24S
88. Eyre DR, Paz MA, Gallop PM. Cross-linking in collagen and elastin. Annu Rev Biochem 1984;53:717-748
89. Knott L, Bailey AJ. Collagen cross-links in mineralizing tissues: a review of their chemistry, function, and clinical relevance. Bone 1998;22:181-187
90. Robins SP. Collagen crosslinks in metabolic bone disease. Acta Orthop Scand 1995;266:171-175
91. Garnero P, Delmas PD. New developments in biochemical markers for osteoporosis. Calcif Tissue Int 1996;59(Suppl 1):S2-S9
92. Pagani F, Francucci CM, Moro L. Markers of bone turnover: biochemical and clinical perspectives. J Endocrinol Invest 2005;28(Suppl 10):8-13
93. Hanson DA, Weis MA, Bollen AM, Maslan SL, Singer FR, Eyre DR. A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine. J Bone Miner Res 1992;7:1251-1258
94. Eyre DR. The specificity of collagen cross-links as markers of bone and connective tissue degradation. Acta Orthop Scand Suppl 1995;266:166-170
95. Apone S, Lee MY, Eyre DR. Osteoclasts generate cross-linked collagen N-telopeptides (NTx) but not free pyridinolines when cultured on human bone. Bone 1997;21:129-136
96. Bonde M, Garnero P, Fledelius C, Qvist P, Delmas PD, Christiansen C. Measurement of bone degradation products in serum using antibodies reactive with an isomerized form of an 8 amino acid sequence of the C-telopeptide of type I collagen. J Bone Miner Res 1997;12:1028-1034
97. Rosenquist C, Fledelius C, Christgau S, Pedersen BJ, Bonde M, Qvist P, Christiansen C. Serum CrossLaps One Step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen. Clin Chem 1998;44:2281-2289
98. Woitge HW, Pecherstorfer M, Li Y, Keck AV, Horn E, Ziegler R, Seibel MJ. Novel serum markers of bone resorption: clinical assessment and comparison with established urinary indices. J Bone Miner Res 1999;14:792-801
99. Janckila AJ, Takahashi K, Sun SZ, Yam LT. Tartrate-resistant acid phosphatase isoform 5b as serum marker for osteoclastic activity. Clin Chem 2001;47:74-80
100. Janckila AJ, Neustadt DH, Nakasato YR, Halleen JM, Hentunen T, Yam LT. Serum tartrate-resistant acid phosphatase isoforms in rheumatoid arthritis. Clin Chim Acta 2002;320:49-58
101. Halleen JM, Alatalo SL, Suominen H, Cheng S, Janckila AJ, Vaananen HK. Tartrate-resistant acid phosphatase 5b: a novel serum marker of bone resorption. J Bone Miner Res 2000;15:1337-1345
102. Alatalo SL, Halleen JM, Hentunen TA, Monkkonen J, Vaananen HK. Rapid screening method for osteoclast differentiation in vitro that measures tartrate-resistant acid phosphatase 5b activity secreted into the culture medium. Clin Chem 2000;46:1751-1754
103. Lam WK, Eastlund DT, Li CY, Yam LT. Biochemical properties of tartrate-resistant acid phosphatase in serum of adults and children. Clin Chem 1978;24:1105-1108
104. Ylipahkala H, Halleen JM, Kaija H, Vihko P, Vaananen HK. Tartrate-resistant acid phosphatase 5B circulates in human serum in complex with alpha2-macroglobulin and calcium. Biochem Biophys Res Commun 2003;308:320-324
105. Halleen JM. Tartrate-resistant acid phosphatase 5B is a specific and sensitive marker of bone resorption. Anticancer Res 2003;23:1027-1029
106. Gallop PM, Lian JB, Hauschka PV. Carboxylated calcium-binding proteins and vitamin K. N Engl J Med 1980;302:1460-1466
107. Nelsestuen GL, Shah AM, Harvey SB. Vitamin K-dependent proteins. Vitam Horm 2000;58:355-389
108. Young MF, Kerr JM, Ibaraki K, Heegaard AM, Robey PG. Structure, expression, and regulation of the major noncollagenous matrix proteins of bone. Clin Orthop 1992;281:275-294
109. Puchacz E, Lian JB, Stein GS, Wozney J, Huebner K, Croce C. Chromosomal localization of the human osteocalcin gene. Endocrinology 1989;124:2648-2650
110. Javed A, Gutierrez S, Montecino M, van Wijnen AJ, Stein JL, Stein GS, Lian JB. Multiple Cbfa/AML sites in the rat osteocalcin promoter are required for basal and vitamin D-responsive transcription and contribute to chromatin organization. Mol Cell Biol 1999;19:7491-7500
111. Sierra J, Villagra A, Paredes R, Cruzat F, Gutierrez S, Javed A, Arriagada G, Olate J, Imschenetzky M, Van Wijnen AJ, Lian JB, Stein GS, Stein JL, Montecino M. Regulation of the bone-specific osteocalcin gene by p300 requires Runx2/Cbfa1 and the vitamin D3 receptor but not p300 intrinsic histone acetyltransferase activity. Mol Cell Biol 2003;23:3339-3351
112. Koeneman KS, Kao C, Ko SC, Yang L, Wada Y, Kallmes DF, Gillenwater JY, Zhau HE, Chung LW, Gardner TA. Osteocalcin-directed gene therapy for prostate-cancer bone metastasis. World J Urol 2000;18:102-110
113. Moss DW. Perspectives in alkaline phosphatase research. Clin Chem 1992;38:2486-2492
114. Smedsrod B, Melkko J, Risteli L, Risteli J. Circulating C-terminal propeptide of type I procollagen is cleared mainly via the mannose receptor in liver endothelial cells. Biochem J 1990;271:345-350
115. Risteli J, Risteh L. Assays of type I procollagen domains and collagen fragments: problems to be solved and future trends. Scand J Clin Lab Invest 1997;227:105-113
116. Terpos E, Politou M, Rahemtulla A. The role of markers of bone remodeling in multiple myeloma. Blood Rev 2005;19:125-142
117. Dresner Pollack R, Rachmilewitz E, Blumenfeld A, Idelson M, Goldfarb AW. Bone mineral metabolism in adults with beta-thalassaemia major and intermedia. Br J Haematol 2000;111:902-907
118. Voskaridou E, Kyrtsonis MC, Terpos E, Skordili M, Theodoropoulos I, Bergele A, Diamanti E, Kalovidouris A, Loutradi A, Loukopoulos D. Bone resorption is increased in young adults with thalassaemia major. Br J Haematol 2001;112:36-41
119. Voskaridou E, Terpos E, Spina G, Patermos J, Rahemtulla A, Loutradi A, Loukopoulos D. Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassaemia. Br J Haematol 2003;123:730-737
120. Lasco A, Morabito N, Gaudio A, Buemi M, Wasniewska M, Frisina N. Effects of hormonal replacement therapy on bone metabolism in young adults with beta-thalassemia major. Osteoporos Int 2001;12:570-575
121. Morabito N, Gaudio A, Lasco A, Atteritano M, Pizzoleo MA, Cincotta M, La Rosa M, Guarino R, Meo A, Frisina N. Osteoprotegerin and RANKL in the pathogenesis of thalassemia-induced osteoporosis: new pieces of the puzzle. J Bone Miner Res 2004;19:722-727
122. Pratelli L, Verri E, Fortini M, Marconi S, Zolezzi C, Fornasari PM, Gamberini MR, De Sanctis V. Chelation therapy and bone metabolism markers in thalassemia major. J Pediatr Endocrinol Metab 2006;19:1335-1342
123. Voskaridou E, Terpos E. Osteoprotegerin to soluble receptor activator of nuclear factor kappa-B ligand ratio is reduced in patients with thalassaemia-related osteoporosis who receive vitamin D3. Eur J Haematol 2005;74:359-361
124. Voskaridou E, Anagnostopoulos A, Konstantopoulos K, Stoupa E, Spyropoulou E, Kiamouris C, Terpos E. Zoledronic acid for the treatment of osteoporosis in patients with beta-thalassemia: results from a single-center, randomized, placebo-controlled trial. Haematologica 2006;91:1193-1202
125. Angelopoulos NG, Gouta A, Katounda E, Rombopoulos G, Kaltzidou V, Kaltsas D, Malaktari S, Athanasiou V, Tolis G. Circulating osteoprotegerin and receptor activator of NF-kappaB ligand system in patients with beta-thalassemia major. J Bone Miner Metab 2007;25:60-67
126. Angelopoulos NG, Goula A, Katounda E, Rombopoulos G, Kaltzidou V, Kaltsas D, Konstandelou E, Tolis G. Markers of bone metabolism in eugonadal female patients with beta-thalassemia major. Pediatr Hematol Oncol 2007;24:481-491
127. Yoskaridou E, Stoupa E, Antoniadou L, Premetis E, Konstantopoulos K, Papassotiriou I, Terpos E. Osteoporosis and osteosclerosis in sickle cell/beta-thalassemia: the role of the RANKL/osteoprotegerin axis. Haematologica 2006;91:813-816
128. Morabito N, Russo GT, Gaudio A, Lasco A, Catalano A, Morini E, Franchina F, Maisano D, La Rosa M, Plota M, Crifò A, Meo A, Frisina N. The "lively" cytokines network in beta-thalassemia major-related osteoporosis. Bone 2007;40:1588-1594
129. Voskaridou E, Plata E, Christoulas D, Xirakia C, Tsaftaridis P, Stoupa E, Papatheodorou A, Terpos, E. Elevation of cystatin-C and reduction of TNF-a in patients with thalassemia after 12 months of deferasirox administration. Haematologica 2008;93(Suppl 1):341 (abstract 860)
130. Dundar U, Kupesiz A, Ozdem S, Gilgil E, Tuncer T, Yesilipek A, Gultekin M. Bone metabolism and mineral density in patients with beta-thalassemia major. Saudi Med J 2007;28:1425-1429
131. Eren E, Yilmaz N. Biochemical markers of bone turnover and bone mineral density in patients with beta-thalassaemia major. Int J Clin Pract 2005;59:46-51
132. Domrongkitchaiporn S, Sirikulchayanonta V, Angchaisuksiri P, Stitchantrakul W, Kanokkantapong C, Rajatanavin R. Abnormalities in bone mineral density and bone histology in thalassemia. J Bone Miner Res 2003;18:1682-1688
133. Perifanis V, Vyzantiadis T, Tziomalos K, Vakalopoulou S, Garipidou V, Athanassiou-Metaxa M, Harsoulis F. Effect of zoledronic acid on markers of bone turnover and mineral density in osteoporotic patients with beta-thalassaemia. Ann Hematol 2007;86:23-30
134. Mahachoklertwattana P, Sirikulchayanonta V, Chuansumrit A, Karnsombat P, Choubtum L, Sriphrapradang A, Domrongkitchaiporn S, Sirisriro R, Rajatanavin R. Bone histomorphometry in children and adolescents with beta-thalassemia disease: iron-associated focal osteomalacia. J Clin Endocrinol Metab 2003;88:3966-3972
135. Scacchl M, Danesi L, Cattaneo A, Valassi E, Giraldi FP, Argento C, D'Angelo E, Mirra N, Carnelli V, Zanaboni L, Tampieri B, Cappellini MD, Cavagnini F. Bone demineralization in adult thalassaemic patients. Contribution of growth hormone and insulin-like growth factor I at different skeletal sites. Clin Endocrinol (Oxf) 2008; in press
136. Voskaridou E, Christoulas D, Xirakia C, Varvagiannis K, Boutsikas G, Terpos E. Serum dickkopf-1 is increased and correlates with bone mineral density in patients with thalassemia-induced osteoporosis. Reduction post zoledronic acid administration. Haematologica 2008;93(Supp 1):357 (abstract 900)
137. Yaccoby S, Ling W, Zhan F, Walker R, Barlogie B, Shaughnessy JD Jr. Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood 2007;109:2106-2111
138. Delmas PD. Bone marker nomenclature. Bone 2001;28:575-576